NON-SMALL CELL LUNG CANCER

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This Phase 3 study compares a new drug, SHR-A2009, to standard chemotherapy for people with advanced EGFR-mutated non-small cell lung cancer whose initial targeted therapy (EGFR TKI) has stopped working. About 498 participants will receive either SHR-A2009 or chemo to see which b…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose previous targeted therapy (EGFR-TKI) has stopped working. The study compares how long the cancer stays under control and overall survival…

This early-stage trial is testing a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with various advanced solid tumors that have spread or come back. The main goals are to find a…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo …

This phase 2 trial tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors. About 534 participants with various cancers, including lung, breast, and brain tu…

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every thre…

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…

This early-phase trial tests a new drug called INBRX-106, given alone or with the immunotherapy Keytruda, in people with advanced solid tumors (like lung, melanoma, head and neck, stomach, kidney, or bladder cancer) that have stopped responding to standard treatments. The study h…

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This early-stage trial tests a precise, high-dose radiation technique called SBRT for lung cancers located near the center of the chest (ultra-central). The goal is to find the highest safe dose that keeps the risk of serious side effects under 30%. About 30 patients will receive…

This study tests a three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with lung cancer that has worsened after initial treatment. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. About 31 participants with …

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal …

This phase 3 trial tests whether a new drug called ensartinib works better than the current standard crizotinib for people with ALK-positive non-small cell lung cancer. About 290 participants who have had up to one prior chemotherapy but no prior ALK inhibitor are randomly assign…

This early-stage trial is testing a new drug called anvumetostat, alone or with other cancer drugs, in about 49 adults with advanced lung or chest tumors that lack a gene called MTAP. The main goals are to find the safest dose and to see what side effects occur. Researchers will …

This study tests an oral drug called mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take the drug daily for up to a year or longer if their cancer s…

This study tests whether eating 3-6 servings of fermented foods daily (like yogurt, kefir, and sauerkraut) can improve how well cancer treatments work in patients with locally advanced rectal cancer or non-small cell lung cancer. The 39 participants are randomly assigned to eithe…

This study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first fi…

This study tests a combination of two oral drugs, alectinib and cobimetinib, in people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see if the combo can shrink tumors. Sixteen adults with stage IV disease are taking part.

This program offers capmatinib, an oral drug, to people with advanced non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is a managed access (compassionate use) program, not a formal study. The goal is to provide potential benefit …

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for 71 people with advanced lung cancer that has spread to the brain. The goal is to see if this approach can stop brain tumors f…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This phase 2 trial is testing whether combining two drugs—nivolumab and ramucirumab—can help control advanced non-small cell lung cancer in people who have already tried immunotherapy. The study will enroll 36 participants and measure how many achieve stable disease or tumor shri…

This study tests two treatments for people with advanced ALK-positive non-small cell lung cancer who haven't had treatment yet. One group gets the targeted drug brigatinib alone, the other gets brigatinib plus chemotherapy. The goal is to see if the combination helps keep the can…

This study tests whether a daily pill called osimertinib can keep early-stage lung cancer from returning after surgery. About 390 adults with a specific gene mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either osimertinib or a placebo for several year…

This phase 3 study tests whether adding chemotherapy to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced non-small-cell lung cancer that has high levels of a protein called PDL1. About 349 adults with stage IV or inoperable stage…

This study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. About 356 adults with certain genetic types of lung cancer will take part. The goal is to see if the drug is safe and shrinks tumors.

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This study tests whether adding savolitinib to the standard drug osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutant, MET-amplified) that has stopped responding to osimertinib alone. About 30 adults will be rando…

This early-stage study tests a new drug called YL202 in about 80 adults with advanced lung or breast cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Participants will receive YL202 and be closely monitored …

This study tests a combination of two drugs, zimberelimab and domvanalimab, as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combination helps control the cancer longer than standa…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-stage study tests an experimental drug called KIN-2787, taken as a pill, in adults with advanced solid tumors (including lung cancer and melanoma) that have certain gene changes (BRAF or NRAS). The main goals are to check safety, find the best dose, and see if the drug…

This early-stage trial tests an experimental drug called RC148, given as an injection, in people with advanced non-small cell lung cancer that has spread. The study looks at how well the drug shrinks tumors, either alone or combined with other treatments. About 121 adults aged 18…

This early-stage study tests a drug called amivantamab, a special antibody that targets two cancer-related proteins (EGFR and cMet). It is given alone or with other treatments to people with advanced non-small cell lung cancer that has spread or cannot be removed. The main goals …

This study tests a new drug called SKB264 against standard chemotherapy in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy (EGFR-TKI). About 376 participants will be randomly assigned to…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or a placebo plus chemo,…

This study tests whether a single, powerful dose of targeted radiation (SBRT) can safely control central non-small cell lung cancer, instead of the usual multiple sessions. About 30 adults with early-stage tumors near the chest center will receive one treatment. Researchers will …

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This phase 3 trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery helps keep the cancer from coming back. It includes 210 adults with stage IB to IIIA non-small cell lung cancer that was completely removed. Participants are randomly assigned…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This phase 2 trial tested a combination of two targeted drugs, tepotinib and osimertinib, in 140 people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and had stopped responding to the standard drug osimertinib. The goal was to see…

This phase 2 study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer who have not yet received EGFR inhibitors. The trial enrolls 25 participants and measures how well the tumo…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This phase 2 study tests an experimental drug called zelenectide pevedotin in 73 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The drug is give…

This study tests whether adding hydroxychloroquine (a malaria drug) to the targeted cancer pill erlotinib can delay drug resistance in people with advanced EGFR-mutant non-small cell lung cancer. About 76 participants will receive either erlotinib alone or erlotinib plus hydroxyc…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The drug is given alone or combined with other anti-cancer agents. The main goals are to check safety, tolerability,…

This phase 2 trial tests taletrectinib, a daily pill, in 217 people with advanced ROS1-positive non-small cell lung cancer or other solid tumors. The main goal is to see if the drug shrinks tumors and how safe it is. Researchers will also measure how long the cancer stays under c…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-phase trial tests an experimental oral drug called HBI-2376 in about 42 people with advanced solid tumors (lung, colon, pancreatic, and others) that have specific KRAS or EGFR gene mutations and have stopped responding to standard treatments. The main goals are to find…

This study tests an experimental drug called ARRY-614 combined with standard immunotherapy drugs (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds a safe dose, …

This phase 2 trial is testing whether giving a higher dose of radiation to the most active parts of a lung tumor can lower the chance of the cancer coming back. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or a boost…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer who have not taken similar drugs before. About 48 participants will receive the combination for up to 6 months. R…

This phase 2 trial is testing whether combining the immunotherapy drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors and control advanced non-small cell lung cancer. About 400 people who have not had prior treatment for metastatic dis…

This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimerti…

This study tests whether adding stereotactic radiotherapy (precise, high-dose radiation) to standard EGFR inhibitor drugs can improve outcomes for people with non-small cell lung cancer that has spread to the brain. About 202 participants whose brain tumors didn't fully shrink af…

This phase 2 trial is testing whether a combination of two immunotherapy drugs, balstilimab and botensilimab, is safe and effective as a first treatment for people with metastatic non-small cell lung cancer (NSCLC) who have not had prior therapy for advanced disease. The study wi…

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side ef…

This early-phase trial is testing a new experimental drug called BI-1910, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have not responded to standard treatments. The main goals are to see if the …

This Phase 3 trial tests whether adding two experimental drugs (oleclumab or monalizumab) to the standard immunotherapy durvalumab can help people with stage III lung cancer that cannot be surgically removed. Participants have already completed chemotherapy and radiation without …

This early-stage trial is testing an oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma that have certain EGFR mutations. The study has two parts: first finding a safe dose, then checking if the drug shrinks tumo…

This phase 3 trial compares a new targeted drug, sacituzumab govitecan, against the standard chemotherapy docetaxel in 603 people with advanced non-small cell lung cancer that has worsened after prior treatments. The main goal is to see if the new drug helps people live longer. T…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This phase 2 trial tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery helps eliminate more cancer in people with stage 1B-3A non-small cell lung cancer. About 126 participants will be randomly assig…

This phase 2 trial tests a combination of the targeted therapy lazertinib plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that got worse after prior lazertinib treatment. …

This early-phase trial tests a cancer-killing virus (VSV-IFNβ-NIS) combined with immunotherapy drugs in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine carcinoma, and renal cell carcinoma. The virus is designed to infect and destroy cancer …

This study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…

This study tests whether combining the drug durvalumab with radiation therapy can delay cancer growth in people with stage II or III non-small cell lung cancer, without using chemotherapy. About 61 adults with newly diagnosed or recurrent cancer are taking part. The goal is to se…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps patients with advanced non-small cell lung cancer complete a full year of immunotherapy. About 114 adults will participate. The goal is to see if this approach improves survival an…

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug works in the body. About 44 adults who…

This study tests a drug called T-DXd (Enhertu) in 27 people with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The goal is to see how well it controls brain tumors and extends life. Participants receive the drug intravenously and are m…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors.…

This study tests a new drug (SI-B001) combined with a standard pill (osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to previous therapies. About 14 adults will receive the combination to see if it can shrink tumors and control the dise…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…

This phase 3 study tests whether adding savolitinib to standard osimertinib helps people with a specific type of advanced lung cancer (EGFR mutation with MET overexpression). About 412 adults with incurable, advanced non-small cell lung cancer will receive either the combination …

This study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stage II-IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, they have su…

This early-stage study tests whether adding tepotinib (a targeted drug) to pembrolizumab (an immunotherapy) can help shrink tumors in people with advanced non-small cell lung cancer. It includes patients whose cancers have or lack a specific MET gene change. The goal is to see if…

This early-phase study tests a new drug, HFB200603, alone or with another drug (tislelizumab) in 83 adults with advanced solid tumors like kidney, lung, or skin cancer. The main goal is to find safe doses and check for side effects. Participants receive increasing doses to see ho…

This study tests whether a shot (subcutaneous injection) of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer that has high PD-L1 levels. About 67 participants will receive either the shot or IV treatment, and researcher…

This study tests an experimental drug called BL-M02D1 in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 14 adults will take part in this e…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find a safe dose and check for side effects. About 72 participants will take par…

This early-phase trial tests a new antibody drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The s…

This study tests a new drug called JDQ443 combined with other therapies in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find safe doses and see if the combinations can shrink or control the cancer. About 74 adults with lun…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This study tests whether adding a special type of radiation to standard immunotherapy before surgery can help prevent lung cancer from coming back. About 90 people with stage III lung cancer that has spread to lymph nodes will receive chemotherapy, then immunotherapy plus radiati…

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participan…

This early-phase study tests a new drug called AB248, either alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have spread. The main goals are to check safety and find the best dose. About 552 people with certain cancers like lung, melan…

This study tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more tumor tissue in patients with advanced non-small cell lung cancer. About 90 participants will receive either chemo-immunotherapy or chemotherapy alone before their operation…

This study tests a drug called DFMO combined with the immunotherapy pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). The goal is to find a safe dose and see if the combination helps shrink tumors. About 45 adults with measurable disease will take part.

This study looks at people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). After 3 weeks on the targeted drug osimertinib, those who still have signs of the mutation in their blood are randomly assigned to either keep taking osimertinib a…

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that targets and attacks cancer cells, with the immunotherapy drug pemb…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. Researchers use a simple blood test to find specific genetic changes in the cancer, then match patients to a treatment that targets those changes. The goal is to shrink …

This study tests whether the immunotherapy drug nivolumab, alone or with chemotherapy, can shrink early-stage non-small cell lung cancer before surgery and help prevent it from coming back after surgery. About 316 people with stage II or IIIA lung cancer that can be removed will …

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This early-phase study tests whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer that has changes in the MET gene. The study includes about 3 adults with advanced lung cancer that cannot be removed by surgery. Researchers will monit…

This study tests whether adding a new drug (uliledlimab) to an immunotherapy (toripalimab) works better than standard immunotherapies alone for people with advanced non-small cell lung cancer that has certain markers (PD-L1 and CD73). About 450 adults who have not had treatment f…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This early-stage trial tests a new daily pill, zongertinib, in adults with advanced cancers that have HER2 gene changes, including non-small cell lung cancer. The first part finds the safest dose; the second checks if it shrinks tumors. Participants stay on the drug as long as it…

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help control advanced non-small cell lung cancer. About 120 adults with stage IV lung cancer will receive either the combination or pembrolizumab alone. The goal is to see if the combination is safe a…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…

This study tests a new drug, JDQ443, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried platinum chemo and an immunotherapy. The goal is to see if…

This study tests whether adding radiation to a standard treatment of immunotherapy (pembrolizumab) plus chemotherapy can help people with advanced non-small cell lung cancer live longer. About 327 participants with stage IIIB or IV disease will receive the combination therapy. Th…

This study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This study tests two targeted drugs, encorafenib and binimetinib, in people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see how well the combination shrinks tumors and controls the disease. About 119 adults are taking part, and…

This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the combination could control the disease for at least 24 weeks. However, the study was withdrawn before …

This early-stage trial tests a new drug (AGEN1181) alone or with another drug (balstilimab) in people with advanced solid tumors that haven't responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 499 adults with …

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This study tested a new treatment plan for people with stage II or III non-small cell lung cancer. Participants first received precise radiation to the main tumor, then standard chemoradiation to the chest, followed by immunotherapy. The goal was to see if this approach could kee…

This study tests whether giving precise radiation to tumors that have just started to grow can delay the cancer from getting worse. It involves 107 adults with metastatic triple-negative breast cancer or non-small cell lung cancer. Participants are randomly assigned to receive ei…

This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer that has worsened after prior treatment with a similar drug. The goal is to see if adding two new drugs can shrink tumors or …

This study tested whether adding the drug abemaciclib to standard care helps people with stage IV lung cancer that has a KRAS mutation live longer. All 453 participants had already tried chemotherapy. Half received abemaciclib plus supportive care, the other half received erlotin…

This study tests whether adding the experimental drug uliledlimab to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is …

This study tests whether adding an investigational drug called fianlimab to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combination alone for people with advanced non-small cell lung cancer. About 950 adults who have not had prior treatment…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that have …

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This study tests a new treatment plan for people with advanced lung cancer that cannot be removed by surgery. The plan uses a mix of chemotherapy and immunotherapy before and after radiation therapy. The goal is to see if this approach can help patients live longer without their …

This study compares a new targeted drug (DZD9008) to standard chemotherapy in people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 324 participants who have not had prior treatment will be randomly assigned to receive either…

This study tests whether a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated…

This early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain genetic markers (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can …

This study tests whether a daily pill called osimertinib can keep lung cancer from coming back after surgery in people with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take the drug for up to 3 years. The main goal is to see ho…

This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already tried immunotherapy. The goal is to see if the triple therapy can shrink tumors and how safe it is. Participants mus…

This study tests the safety of adding an experimental drug (MPDL3280A) to standard chemotherapy and radiation for people with non-small cell lung cancer that cannot be removed by surgery. About 52 participants will receive the combination therapy at MD Anderson Cancer Center. The…

This study tests a precise type of radiation (SABR) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. About 39 participa…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participants will …

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better …

This study tests a new drug called BL-B01D1, given alone or with another drug (osimertinib), in people with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and how safe it is. About 198 adults with this type of lung cancer will take part.

This study tests an experimental drug called AB-106 in 173 adults with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive AB-106 alone, and thei…

This study tests whether the drug atezolizumab can help prevent non-small cell lung cancer from coming back after surgery and chemotherapy. About 1,280 people with stage IB to IIIA lung cancer took part. Half received atezolizumab for about a year, and half received standard moni…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This study tests a new approach for people with stage IV non-small cell lung cancer that has spread to only a few other places (oligometastatic). Participants receive immunotherapy and chemotherapy, plus precise radiation to the metastases, followed by surgery or radiation to the…

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not received prior treatment for their advanced cancer. The goal is to see if the drug helps them live longer and co…

This study tests whether giving the immunotherapy drug durvalumab together with standard chemotherapy before surgery or radiation can help people with stage IIB to IIIB non-small cell lung cancer. Participants first receive the drug combination, then either have surgery followed …

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests whether giving the targeted drug osimertinib, alone or with chemotherapy, before surgery can shrink tumors more than chemotherapy alone in people with a specific genetic mutation (EGFR) in early-stage lung cancer. About 358 adults with resectable non-small cell l…

This study compares a new drug, BL-B01D1, to the standard chemo docetaxel in people with advanced non-small cell lung cancer that has not responded to previous treatments. About 698 adults whose cancer has spread or cannot be removed will take part. The goal is to see if BL-B01D1…

This study tests a combination of two drugs (tuvusertib and cemiplimab) in people with a type of advanced lung cancer that has stopped responding to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. About 61 participants will take p…

This study tests whether adding ramucirumab to the standard drug osimertinib can better control advanced EGFR-mutant lung cancer. About 160 people with non-squamous non-small cell lung cancer that cannot be surgically removed will be randomly assigned to receive either the combin…

This study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…

This study tests a pill called sunvozertinib given before surgery to people with a certain type of lung cancer (stage II-IIIB non-small cell lung cancer with EGFR exon 20 insertion mutations). The goal is to see if the drug can shrink tumors and improve surgical outcomes. About 2…

This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…

This study looks at whether adding a special type of radiation (SABR) to standard cancer therapy can help people with non-small cell lung cancer that has spread to only a few spots in the body. About 140 adults will be randomly assigned to get either standard treatment alone or s…

This early-phase trial tests a treatment for people with advanced solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. The approach uses a person's own white blood cells, which are modified in a lab to better recognize and attack…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This study is testing a new drug called DZD9008 in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes and has stopped responding to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it …

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior tr…

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …

This study looks at a new lab technique called OSNA that may find tiny amounts of cancer in lymph nodes better than current methods. About 130 people with early-stage lung cancer having robotic surgery will take part. Half will have their lymph nodes checked with OSNA, the other …

This study looks at whether a simple blood test (liquid biopsy) can help doctors decide on lung cancer treatment faster than the usual method of testing tumor tissue. About 170 adults with advanced non-small cell lung cancer will have their blood tested for genetic changes. The g…

This study tests whether giving trilaciclib before chemotherapy can prevent bone marrow suppression in people with advanced non-small cell lung cancer. About 41 participants will receive the drug before their standard platinum-based chemo. The main goal is to see if it reduces se…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests whether adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer. Sixty participants will receive either real or sham acupuncture alongside their first four treatment cycles. The goal is to see if acupunc…

This study tests whether a progressive exercise program can reduce chronic pain in veteran lung cancer survivors aged 60-80. Nine participants will do treadmill walking, resistance bands, and balance exercises. The goal is to see if exercise can be a safe alternative to opioids f…

This study tests a new support program for adults with lung cancer or mesothelioma who have finished treatment. The goal is to help them improve their quality of life as they move from active treatment to regular check-ups. About 21 participants will try the program to see if it …

This study looks at whether PET-CT scans can predict if non-small cell lung cancer has spread to nearby lymph nodes. Researchers will compare two types of PET-CT scans (using different tracers) with the actual results from surgery. The goal is to see if these scans can help docto…

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…

This study looks at how the heart works during a 6-minute walk test in people with advanced lung cancer who are getting chemotherapy, radiation, and immunotherapy. The goal is to see if heart measurements can help predict side effects and how well patients do over time. About 231…

This study screens up to 1,150 adults with advanced solid tumors (like head and neck, cervical, or lung cancer) to see if they have the right genetic markers and tumor features for future T-cell therapies. Researchers will test blood and tumor samples for HLA type and other marke…

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacter…

This study looks at how doctors use the VeriStrat blood test to decide treatments for people with non-small cell lung cancer. About 5,000 patients are being observed to see if the test results change treatment plans and improve outcomes. The goal is to learn how to better persona…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study looks at circulating tumor cells (CTCs) in the blood of 80 people with advanced lung cancer. Researchers will grow these cells in the lab to test new drugs that target DNA repair. The goal is to learn how to personalize treatment based on each person's tumor cell featu…

This study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults will have blood samples taken before and during their standard treatment. The …

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study compares two minimally invasive surgeries for early-stage lung cancer: robotic-assisted surgery and video-assisted thoracoscopic surgery (VATS). Both use small incisions, but robotic surgery offers 3D imaging and more precise instrument control. The goal is to see whic…

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced lung cancer compared to usual care. About 659 participants with stage IIb-IV non-small cell lung cancer will be followed to see if the expert approach…

This study looks at people with suspected or confirmed non-small cell lung cancer who need a tissue sample for genetic testing. It compares taking 2 versus 3 samples from each lymph node during an ultrasound-guided biopsy to see which method gives enough material for testing. It …

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study gives the immunotherapy drug durvalumab to people with operable non-small cell lung cancer before their surgery. The main goal is to see how the drug changes the tumor and immune system, not to cure the disease. About 25 adults with stage IIA to IIIB lung cancer will t…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study looks at how detailed analysis of PET/CT scans, combined with artificial intelligence, can help doctors better understand non-small cell lung cancer. Researchers will use data from 500 patients to build models that predict cancer stage, genetic changes, and patient out…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…

This study follows up to 400 people who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The goal is to track long-term side effects and see how well the treatment effects last over time. No new treatment is given—par…

This study compares two common treatments for stage I non-small cell lung cancer: surgery and stereotactic body radiation therapy (SBRT). About 446 patients will report their quality of life and symptoms for up to 3 years after treatment. The goal is to see which approach offers …

This study looks at whether a blood test that detects tumor DNA can help doctors decide when to stop immunotherapy in people with advanced melanoma or lung cancer. About 39 adults who have been on immunotherapy for at least a year and show good response will be followed. The goal…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study aims to collect medical history and tissue or saliva samples from 100 people with a specific type of advanced lung cancer called ALK+ non-small cell lung cancer. Researchers will analyze these samples to better understand the genetic and immune features of the disease.…

This study collects and analyzes lung cancer tissue samples from 500 patients in Asia to find out which genetic changes are most common. The goal is to better understand the disease in the local population. Participants must have a tissue sample available and be healthy enough fo…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study looks at how doctors in Russia treat advanced or metastatic non-small-cell lung cancer in everyday practice. Researchers will follow about 1500 adults across 20 cancer centers to see which treatments and genetic tests are used. The goal is to understand real-world care…

This study looks back at 46 adults with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers want to see which treatment strategies worked best by tracking how long patients stayed free of cancer growth. The goal is to find a standard app…